generation run 2026-04-24
60 min completedmodel pipeline-v5plan not recordedrun/b1234cba…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
none raised on this run
Reproduce
- inputs
- 28 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | 4-HO-MET forensic toxicology detection urine | 3 | 2 | Theofel provides polydrug fatality context; Tang provides analytical interference data |
| 2 | PubMed | 4-hydroxy tryptamine new psychoactive substance NPS tryptamine hallucinogen | 3 | 1 | Grafinger confirms 4-HO-MET metabolic pathways |
| 3 | PubMed | 4-HO-MET 4-hydroxy-N-methyl-N-ethyltryptamine pharmacology | 5 | 5 | All 5 papers are directly about 4-HO-MET |
| 4 | OpenAlex | tryptamine NPS new psychoactive substance forensic detection scheduling regulation | 8 | 3 | Tittarelli is the most cited review of tryptamine NPS; Baumeister provides legal/scheduling context |
| 5 | PubChem | 4-HO-MET | 1 | 1 | Single confirmed compound entry for 4-HO-MET |
| 6 | PubMed · absence | psilocybin psilocin 5-HT2A agonist binding receptor pharmacokinetics | 0 | — | No useful results |
| 7 | PubMed · absence | metocin tryptamine psychedelic serotonin receptor | 0 | — | No unique results |
| 8 | ClinicalTrials.gov · absence | 4-HO-MET metocin tryptamine psychedelic | 0 | — | Confirms absence of clinical trial activity |
| 9 | PubMed | serotonin syndrome hallucinogen tryptamine serotonergic toxicity mechanism | 6 | 1 | Directly relevant to tramadol and serotonergic interaction risks |
| 10 | PubMed | 5-HT2A receptor tolerance downregulation psychedelic tryptamine DOI LSD | 1 | 1 | Directly cited in brief as mechanistic source for tolerance data |
| 11 | OpenAlex | 4-hydroxy-N-methyl-N-ethyltryptamine 5-HT2A receptor binding functional activity | 8 | 4 | All relevant to receptor pharmacology of 4-hydroxytryptamines |
| 12 | PubMed | Simonsson Hendricks challenging distressing psychedelic experience lithium risk 2023 | 1 | 1 | Epidemiological evidence for lithium-psychedelic interaction risk |
| 13 | PubMed | Gatch Hoch Carbonaro discriminative stimulus substituted tryptamines 2020 | 1 | 1 | Direct behavioral evidence for hallucinogen-like effects of 4-HO-MET in rats |
| 14 | PubMed+Crossref | Kozell 2023 JPET substituted tryptamines 5-HT2A binding | 1 | 1 | Best candidate source for quantitative receptor binding data |
| 15 | WebSearch | 4-HO-MET metocin synthesis history Shulgin TiHKAL first synthesis | 10 | 2 | Establishes historical record |
| 16 | WebSearch | 4-HO-MET legal status United States UK Australia Canada scheduling analog act | 10 | 2 | Multiple sources confirming legal status |
| 17 | Erowid | TiHKAL entry 21 4-HO-MET Shulgin | 1 | 1 | Primary historical record; physical properties; Shulgin's experiential commentary |
| 18 | OpenAlex | psilocybin psilocin pharmacokinetics metabolism CYP | 5 | 2 | Provide class-level CYP and DDI framework for 4-HO-MET |
| 19 | NCATS Inxight Drugs | 4-HO-MET SMILES receptor binding | 1 | 1 | Only published receptor binding values found for 4-HO-MET |
| 20 | WebSearch | 4-HO-MET legal status Germany Netherlands Sweden Europe NPS controlled | 10 | 2 | EU jurisdiction legal status |
| 21 | Crossref | DOI verification 10.1002/jhet.5570180131 | 1 | 1 | Confirms Repke 1981 as first published synthesis |
| 22 | Crossref | DOI verification 10.1021/acsomega.5c10889 Barovic 4-HO-MET commercial | 1 | 1 | Most recent primary research on 4-HO-MET market presence |
| 23 | ClinicalTrials.gov · absence | 4-HO-MET metocin tryptamine | 0 | — | Confirms absence of clinical development |
80 claims by section — every cited sentence, checked against its source
safety27 · 19 ok
The only published human exposure measurement is a blood plasma concentration of 193 ng/mL from a non-fatal clinical intoxication case, detected by LC-HRMS/MSsupported
Blood plasma concentration 193 ng/mL... LC-HRMS/MS confirmed detection. bkab062
One polydrug fatality has been reported in which 4-HO-MET was present alongside 4-HO-MiPT, 4-AcO-DET, designer benzodiazepines (clonazolam, flualprazolam), and opiates in a 21-year-old male; death was attributed to the benzodiazepines and opiates, not to the tryptaminessupported
Primary cause of death attributed to designer benzodiazepines and opiates. Provides mass spectra of 4-HO-MET. bkac098
Yoon et al. (2020) demonstrated hERG potassium channel inhibition in Chinese Hamster Ovary (CHO) cells expressing hERG channels and QT interval prolongation confirmed by ECG in Sprague-Dawley rats in vivosupported
Both substances increased QT intervals in Sprague-Dawley rats and inhibited hERG potassium channels in CHO cells. j.toxlet.2019.10.022
The broader context for cardiovascular risk is provided by Wsól (2023): 5-HT₂A/2B agonism is associated with platelet aggregation and proarrhythmic potential across the psychedelic classsupported
5-HT2A/2B and 5-HT4 agonism discussed as sources of potential cardiotoxicity. Proarrhythmic potential and platelet aggregation effects noted. s43440-023-00539-4
GC-MS fails to detect 4-HO-MET in blood samples; LC-HRMS/MS or LC-ITMSn are requiredsupported
LC-HRMS/MS confirmed detection. GC-MS failed to detect compound. bkab062
A clinically significant analytical interference exists: N-despropyl-ropinirole, a metabolite of the dopamine agonist ropinirole, mimics 4-HO-MET on LC-MS/MS due to structural similaritysupported
N-despropyl-ropinirole (ropinirole metabolite) shares structural similarities with 4-HO-MET causing false positives in LC-MS/MS screening. j.forsciint.2021.111151
Claim in safety — inconclusiveinconclusiveworking →
In the phenomenological study by Kjellgren and Soussan (2011), approximately half of the 25 analyzed experience reports described intensely negative states — termed "hell" — characterized by anxiety, paranoia, and acute distress, sometimes occurring within the same session as positive experiencessupported
Experiences shifted between 'heaven' and 'hell'; participants satisfied and willing to repeat. pmid:22111404
Simonsson et al. (2023) found in a nationally representative US sample (N = 2,822 adults; 613 lifetime classic psychedelic users) that challenging psychedelic experiences were statistically associated with set and setting variables in covariate-adjusted regression modelssupported
US nationally representative data (N=2,822). Among 613 lifetime classic psychedelic users... Six set/setting variables also associated. j.jad.2023.01.073
De la Fuente Revenga et al. (2022) demonstrated in mice that a single dose of the 5-HT₂A agonist DOI produced detectable tolerance within 24 hours, with progressive tolerance following 4 days of repeated dosingsupported
Repeated DOI (4 days) produced progressive HTR decrease in mice. Tolerance detectable within 24h of single dose. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Physical and psychological dependence liability is negligible. 4-HO-MET does not engage dopaminergic reward circuitry (VTA-NAc pathway) at pharmacologically relevant concentrations, and the rapid tachyphylaxis via 5-HT₂A downregulation is self-limiting — repeated daily use produces diminishing returns rather than escalating reinforcement.supported
Repeated DOI (4 days) produced progressive HTR decrease... DOI → 5-HT2A downregulation in frontal cortex membrane preparations. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
Yu (2008) identifies drug-drug interactions for indolealkylamines at both pharmacokinetic (CYP2D6 competition) and pharmacodynamic (additive serotonergic stimulation) levels.supported
DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5
Rached et al. (2026) document fatalities for MAOI combinations with serotonergic tryptamines including DMT and 5-MeO-DMTsupported
Fatalities reported for MAOIs + 5-MeO-DMT, amphetamine, MDMA... s40263-025-01256-7
Simonsson et al. (2023) found that lithium co-use was significantly associated with both degree of difficulty during challenging psychedelic experiences and overall risk of harm in covariate-adjusted regression modelssupported
Co-use of lithium and mood stabilizers significantly associated with degree of difficulty and overall risk of harm. j.jad.2023.01.073
Halman et al. (2024) identify lithium as a relevant co-medication in the psychedelic drug interaction context in their systematic reviewsupported
Interactions with antidepressants, antipsychotics, anxiolytics, mood stabilisers, recreational drugs. 02698811231211219
Kuc et al. (2022) confirmed dose-dependent modulation of the psychedelic experience by cannabis in a prospective online survey, though causal direction and clinical significance remain unclearsupported
Dose-dependent modulation of psychedelic experience by cannabis confirmed. s00213-021-05999-1
Claim in safety — inconclusiveinconclusiveworking →
Based on substance-specific data — Yoon et al. (2020) demonstrated hERG channel inhibition and QT prolongation for 4-HO-MET — concurrent use of QT-prolonging medications creates additive arrhythmia risksupported
Both substances increased QT intervals in Sprague-Dawley rats and inhibited hERG potassium channels in CHO cells. j.toxlet.2019.10.022
Cardiac arrhythmias and QT prolongation: hERG inhibition and QT prolongation demonstrated for 4-HO-MET in preclinical models support absolute contraindication in individuals with pre-existing long QT syndrome, congenital arrhythmias, or concurrent QT-prolonging medication use.supported
Both substances increased QT intervals in Sprague-Dawley rats and inhibited hERG potassium channels in CHO cells. Suggests potential adverse cardiovascular effects. j.toxlet.2019.10.022
Claim in safety — inconclusiveinconclusiveworking →
The lithium interaction data further support avoidance in individuals on lithium therapy.supported
Co-use of lithium and mood stabilizers significantly associated with degree of difficulty and overall risk of harm. j.jad.2023.01.073
Hepatic impairment: Twelve phase I metabolites identified via pHLM indicate substantial hepatic processingsupported
12 phase I metabolites identified via pHLM in vitro model. j.forsciint.2018.06.037
Claim in safety — inconclusiveinconclusiveworking →
pharmacology17 · 10 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
4-HO-MET acts as a direct agonist at the serotonin 5-HT₂A receptor, the primary molecular target mediating classical psychedelic effectssupported
Tryptamines are 5-HT2A agonists... 4-HO-MET included as emerging NPS. ijms21239279
Recommended forensic markers include the N-oxide, HO-alkyl metabolites, and glucuronide conjugates of 4-HO-MET and the parent compound.supported
Recommended forensic targets: N-oxide and HO-alkyl metabolites plus glucuronides. j.forsciint.2018.06.037
Claim in pharmacology — inconclusiveinconclusiveworking →
Additional activity at 5-HT₂C and 5-HT₁A is consistent with the receptor profile of 4-substituted tryptamines characterized by Glatfelter et al. (2023)supported
Determined receptor binding profiles for tryptamine psychedelics structurally related to psilocybin including N,N-methyl-ethyl substituted compounds (4-HO-MET equivalent). Multiple serotonin receptor targets including 5-HT1A. acsptsci.2c00222
Claim in pharmacology — inconclusiveinconclusiveworking →
Gatch et al. (2021) demonstrated that 4-HO-MET fully substituted for the discriminative stimulus effects of the hallucinogen DOM (2,5-dimethoxy-4-methylamphetamine) in Sprague-Dawley rats, confirming 5-HT₂A-mediated hallucinogen-like pharmacology in vivosupported
4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats. acsptsci.0c00173
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Bruni et al. (2018) characterized the metabolic pathway using pooled human liver microsomes (pHLM), identifying 12 phase I metabolitessupported
12 phase I metabolites identified via pHLM in vitro model. j.forsciint.2018.06.037
Grafinger et al. (2019) confirmed compatible metabolic pathways using the microbial model Cunninghamella elegans.supported
C. elegans metabolized DMT, 4-HO-MET, 5-MeO-DALT, 5-MeO-MiPT... Confirms major metabolic pathways for 4-HO-MET. dta.2544
In vivo confirmation from authentic human urine samples (n = 3) identified 4 metabolites, with monohydroxylation and glucuronidation (phase II) predominatingsupported
4 in vivo metabolites detected in authentic urine samples... In vivo: monohydroxylation and glucuronidation. j.forsciint.2018.06.037
In a non-fatal intoxication case, Wagmann et al. (2022) detected N-demethyl-4-HO-MET, oxo-4-HO-MET, hydroxy-4-HO-MET, and the N-oxide in blood plasmasupported
Four metabolites identified in blood: N-demethyl-, oxo-, hydroxy-4-HO-MET, and N-oxide. bkab062
Claim in pharmacology — inconclusiveinconclusiveworking →
The only published human plasma concentration is 193 ng/mL, measured by LC-HRMS/MS (standard addition method) in a non-fatal clinical intoxication casesupported
Blood plasma concentration 193 ng/mL... LC-HRMS/MS confirmed detection. bkab062
The 12-metabolite pHLM profile establishes that hepatic microsomal processing is substantial, and severe hepatic impairment could plausibly alter pharmacokinetics — though this remains a class-level inference.supported
12 phase I metabolites identified via pHLM in vitro model. j.forsciint.2018.06.037
summary10 · 8 ok
Claim in summary — inconclusiveinconclusiveworking →
The published evidence base consists of one phenomenological study of subjective effects, one in vitro/in vivo cardiotoxicity study, metabolic pathway characterization, and scattered case reportssupported
Qualitative analysis of 25 anonymous Swedish experience reports (ages 18-30) from public Internet forums. EPP method produced 37 categories compiled into 9 themes. pmid:22111404
The published evidence base consists of one phenomenological study of subjective effects, one in vitro/in vivo cardiotoxicity study, metabolic pathway characterization, and scattered case reportssupported
Evaluated cardiotoxicity of 4-AcO-DET and 4-HO-MET via MTT assay, ECG, and hERG assay. j.toxlet.2019.10.022
The published evidence base consists of one phenomenological study of subjective effects, one in vitro/in vivo cardiotoxicity study, metabolic pathway characterization, and scattered case reportssupported
12 phase I metabolites identified via pHLM in vitro model; 4 in vivo metabolites detected in authentic urine samples. j.forsciint.2018.06.037
In drug discrimination studies, it fully substitutes for the hallucinogen DOM in rats, confirming 5-HT₂A-mediated psychedelic pharmacology in vivosupported
4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats. acsptsci.0c00173
The experiential profile encompasses pronounced alterations in color perception, form constants, synesthesia, lateral cognition, and ego boundary dissolution, with both intensely positive and intensely negative states documented within single sessionssupported
Drastic changes in cognitive, emotional, and bodily functions... Experiences shifted between 'heaven' and 'hell'. pmid:22111404
No LD₅₀ has been determined for any species; the sole human plasma measurement (193 ng/mL) derives from a single non-fatal intoxication case. In vitro hERG channel inhibition and in vivo QT prolongation in rats indicate potential cardiotoxicity, though human cardiac risk at recreational doses remains unquantifiedsupported
Non-fatal clinical toxicology case involving 4-HO-MET. Blood plasma concentration 193 ng/mL. bkab062
No LD₅₀ has been determined for any species; the sole human plasma measurement (193 ng/mL) derives from a single non-fatal intoxication case. In vitro hERG channel inhibition and in vivo QT prolongation in rats indicate potential cardiotoxicity, though human cardiac risk at recreational doses remains unquantifiedsupported
Both substances increased QT intervals in Sprague-Dawley rats and inhibited hERG potassium channels in CHO cells. Suggests potential adverse cardiovascular effects. j.toxlet.2019.10.022
Tolerance develops rapidly through 5-HT₂A receptor downregulation, with cross-tolerance expected across serotonergic psychedelics; physical and psychological dependence liability is negligible given the absence of dopaminergic reward pathway engagementsupported
Tolerance detectable within 24h of single dose... Cross-tolerance between DOI and LSD confirmed... DOI → 5-HT2A downregulation in frontal cortex membrane preparations. acschemneuro.2c00170
Claim in summary — inconclusiveinconclusiveworking →
pharmacokinetic-detail7 · 6 ok
Wagmann et al. (2022) identified N-demethyl-4-HO-MET, oxo-4-HO-MET, hydroxy-4-HO-MET, and the N-oxide in blood plasma from a non-fatal intoxication case.supported
Four metabolites identified in blood: N-demethyl-, oxo-, hydroxy-4-HO-MET, and N-oxide. LC-HRMS/MS confirmed detection. bkab062
The sole published plasma concentration — 193 ng/mL in a clinical intoxication case — represents a single time-point from a non-fatal exposure without known dose, timing relative to ingestion, or serial sampling.supported
Non-fatal clinical toxicology case involving 4-HO-MET. Blood plasma concentration 193 ng/mL. bkab062
Yu (2008) identifies pharmacokinetic DDI risk for indolealkylamines through CYP2D6 inhibition by co-administered drugs, which could elevate plasma tryptamine concentrations and increase serotonin toxicity risksupported
CYP2D6 plays important polymorphic role in metabolism of IAA drugs of abuse... DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5
Monoamine oxidase inhibitors would be expected to dramatically increase exposure by blocking primary metabolic clearance pathways — a mechanism associated with fatalities in related tryptamine-MAOI combinations.supported
Fatalities reported for MAOIs + 5-MeO-DMT, amphetamine, MDMA... s40263-025-01256-7
In vivo urine analysis (n = 3 authentic samples) confirmed 4 of these metabolites, with monohydroxylation and phase II glucuronidation predominatingsupported
4 in vivo metabolites detected in authentic urine samples... In vivo: monohydroxylation and glucuronidation. j.forsciint.2018.06.037
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Bruni et al. (2018) identified 12 phase I metabolites via pooled human liver microsome (pHLM) incubation:supported
12 phase I metabolites identified via pHLM in vitro model. j.forsciint.2018.06.037
clinical-evidence4 · 3 ok
Non-fatal intoxication: Wagmann et al. (2022) documented a clinical intoxication case with blood plasma concentration of 193 ng/mL, confirming survivability at clinical presentation levels.supported
Non-fatal clinical toxicology case involving 4-HO-MET. Blood plasma concentration 193 ng/mL. bkab062
Polydrug fatality: Theofel et al. (2023) reported 4-HO-MET presence alongside 4-HO-MiPT and 4-AcO-DET in a fatal case attributed primarily to designer benzodiazepines (clonazolam, flualprazolam) and opiates.supported
4-HO-MET found among substances near deceased (alongside 4-HO-MiPT, 4-AcO-DET). Primary cause of death attributed to designer benzodiazepines and opiates. bkac098
Phenomenological study: Kjellgren and Soussan (2011) conducted a qualitative phenomenological analysis of 25 anonymous Swedish internet experience reports using the Empirical Phenomenological Psychological (EPP) method, identifying nine experiential themes including perceptual distortion, lateral cognition, ego boundary dissolution, and both euphoric and distressing states.supported
Qualitative analysis of 25 anonymous Swedish experience reports (ages 18-30) from public Internet forums. EPP method produced 37 categories compiled into 9 themes... Experiences shifted between 'heaven' and 'hell'. pmid:22111404
Claim in clinical-evidence — inconclusiveinconclusiveworking →
chemistry3 · 1 ok
The 4-hydroxyl group on the indole ring is the pharmacophore responsible for 5-HT₂A receptor agonism in this class.supported
SAR study of fluorinated tryptamine analogues at 5-HT2A, 5-HT2C, 5-HT1A. Establishes SAR framework for 4-hydroxytryptamine class. pmid:11101361
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
comparative-pharmacology3 · 3 ok
In drug discrimination assays, Gatch et al. (2021) found that all three 4-hydroxy compounds fully substituted for DOM, with comparable potenciessupported
4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats. N-methyl-N-ethyl compounds showed similar potency to N,N-dimethyl and N,N-diethyl. acsptsci.0c00173
The metabolic profile — predominantly hydroxylation, N-dealkylation, and glucuronidation — parallels the biotransformation patterns described for other 4-hydroxytryptamines.supported
Predominant biotransformations: mono/dihydroxylation, demethylation, carboxylic acid formation, deethylation, oxidative deamination. In vivo: monohydroxylation and glucuronidation. j.forsciint.2018.06.037
Yoon et al. (2020) studied both 4-HO-MET and 4-AcO-DET in the same experimental paradigm, finding hERG channel inhibition and QT prolongation for both compounds in CHO cells and Sprague-Dawley ratssupported
Evaluated cardiotoxicity of 4-AcO-DET and 4-HO-MET via MTT assay, ECG, and hERG assay. Both substances increased QT intervals in Sprague-Dawley rats and inhibited hERG potassium channels in CHO cells. j.toxlet.2019.10.022
history3 · 2 ok
Barovic et al. (2026) confirmed its presence in commercially available tablets marketed as "Party Duck" (mean 1.45 mg/tablet, 2.82 mg/g) and in unlabeled powder in the United States, demonstrating ongoing exploitation of regulatory gaps in jurisdictions where the compound is not specifically scheduledsupported
4-HO-MET detected in commercially available tablets (marketed as 'Party Duck') and unlabeled powder... Mean concentration: 2.82 mg/g or 1.45 mg/tablet. Demonstrates exploitation of regulatory loopholes for tryptamine analogues. acsomega.5c10889
Claim in history — inconclusiveinconclusiveworking →
By 2011, Swedish internet forums documented established recreational use patterns among users aged 18–30supported
Qualitative analysis of 25 anonymous Swedish experience reports (ages 18-30) from public Internet forums. pmid:22111404
neuroscience2 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
The phenomenology reported for 4-HO-MET — perceptual distortions, ego boundary dissolution, lateral cognition, and bidirectional emotional intensification — maps onto several neuroscientific frameworks:supported
Drastic changes in cognitive, emotional, and bodily functions. Effects similar to LSD/psilocybin. pmid:22111404
receptor-pharmacology2 · 2 ok
The NCATS Inxight Drugs database reports the following binding and functional activity values, attributed to Kozell et al. (2023):supported
Pharmacological activity of 21 substituted tryptamines at 5-HT2A, 5-HT2C, 5-HT1A receptors and SERT. jpet.122.001454
The selectivity profile — approximately 4-fold selectivity for 5-HT₂A over 5-HT₂C and 6-fold over 5-HT₁A — is consistent with the binding profiles of related 4-hydroxytryptamines characterized by Glatfelter et al. (2023)supported
Determined receptor binding profiles for tryptamine psychedelics structurally related to psilocybin including N,N-methyl-ethyl substituted compounds (4-HO-MET equivalent). Multiple serotonin receptor targets including 5-HT1A. acsptsci.2c00222
effects-overview1 · 1 ok
Across both routes, the experience can pivot rapidly between intensely positive and intensely negative states within a single session; Kjellgren and Soussan (2011) documented this bipolar range as a defining feature, with most users reporting both "heaven" and "hell" domains.supported
Experiences shifted between 'heaven' and 'hell'; participants satisfied and willing to repeat. pmid:22111404
legal-status1 · 1 ok
The ongoing availability of 4-HO-MET in commercial products — confirmed by Barovic et al. (2026) — demonstrates that the patchwork regulatory landscape allows continued manufacture and distribution through jurisdictions lacking specific controls.supported
4-HO-MET detected in commercially available tablets (marketed as 'Party Duck') and unlabeled powder... Demonstrates exploitation of regulatory loopholes for tryptamine analogues. acsomega.5c10889